P/E ratio for Novavax (NVAX)

P/E ratio history for Novavax from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Agenus AGEN	-4.11	260.54%	🇺🇸 USA
Sarepta Therapeutics SRPT	-13.9	1,118.35%	🇺🇸 USA
Emergent BioSolutions EBS	-0.7964	-30.07%	🇺🇸 USA
BioCryst Pharmaceuticals BCRX	-7.23	534.69%	🇺🇸 USA
AstraZeneca AZN	37.2	-3,363.13%	🇬🇧 UK
Pfizer PFE	13.8	-1,308.80%	🇺🇸 USA
Novartis NVS	28.3	-2,587.33%	🇨🇭 Switzerland
NanoViricides NNVC	-2.27	99.43%	🇺🇸 USA
GlaxoSmithKline GSK	10.4	-1,009.03%	🇬🇧 UK
Celldex Therapeutics CLDX	-9.39	724.50%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.